

The Workers Compensation Board (WCB) has developed a draft policy on medical cannabis as a treatment option for work-related injuries or diseases.

Currently, approval of medical cannabis is considered only under exceptional circumstances, as set out in WCB policy, Medications (POL-120). The proposed new policy provides further explanation of the criteria for the approval of medical cannabis. The purpose of the policy is to facilitate the WCB's provision of appropriate medical aid in a responsible and cost-effective manner, and to increase understanding among injured workers, employers, health care providers and other stakeholders about the specific criteria for medical cannabis approval.

The WCB acknowledges that the medical evidence supporting the effectiveness of cannabis treatment is emerging. The proposed policy is based on current research and prescribing guidelines for physicians, and will be reviewed regularly to ensure that the policy aligns with accepted medical practices and the growing body of medical evidence related to cannabis treatment.

---

## Overview of the Proposed Policy

The proposed policy sets out the specific circumstances, criteria and conditions under which medical cannabis may be approved as a treatment for work-related injuries or diseases, including:

- Specific injuries, diseases and symptoms for which medical cannabis may be approved.
- Allowable quantity, price, route and chemical composition of medical cannabis.
- Criteria for trial approval of medical cannabis.
- Safeguards to ensure that risks are assessed and monitored.
- Expectations related to prescribing protocols.
- Conditions under which approval may be suspended or discontinued.

For more information, please refer to the [draft policy](#).

---

## Feedback

Please provide your feedback by September 2, 2018, either [online](#) or in writing to:

Workers Compensation Board- Policy Feedback  
14 Weymouth St, PO Box 757  
Charlottetown, PE C1A 7L7 [policyupdates@wcb.p.ei](mailto:policyupdates@wcb.p.ei)